Axial Therapeutics to Present at Virtual Jefferies Microbiome-based Therapeutics Summit

b'Axial Therapeutics Inc., a clinical-stage biopharmaceutical company dedicated to the development of gut-targeted, small molecule therapeutics for neurological conditions and oncology, today announced that A. Stewart Campbell, Ph.D., chief executive officer, will present an overview of the company and take part in one-on-one meetings with institutional investors at the Jefferies Microbiome-based Therapeutics Summit on April 22, 2021.

Metadata
Provider: 
Business Wire, Inc.Business Wire, Inc.
Retrieved on: 
Thursday, April 15, 2021
Information
Tags: 
Mental health, Research, Biotechnology, Other Health, Health, Pharmaceutical, Other Science, Science, Oncology, Life sciences, Biotechnology, Biopharmaceutical, Pharmaceutical industry, Pharmacy
Geotags: 
United States, Massachusetts
⚠ generated by AI ↴
Organisation: 
AXIAL THERAPEUTICS
Summary
Key Points: 
  • b'Axial Therapeutics Inc., a clinical-stage biopharmaceutical company dedicated to the development of gut-targeted, small molecule therapeutics for neurological conditions and oncology, today announced that A. Stewart Campbell, Ph.D., chief executive officer, will present an overview of the company and take part in one-on-one meetings with institutional investors at the Jefferies Microbiome-based Therapeutics Summit on April 22, 2021.
  • The summit is a virtual event and the presentation will be accessible to conference registrants for 30 days.\nAxial Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of gut-targeted, small molecule therapeutics to treat neurological conditions and cancer.
  • Axial is advancing a pipeline of product candidates with lead clinical programs that address underlying pathology and resulting symptoms in Autism Spectrum Disorder (ASD) and Parkinson\xe2\x80\x99s Disease (PD).
  • For more information, visit https://axialtx.com .\nView source version on businesswire.com: https://www.businesswire.com/news/home/20210415005085/en/\n'


Axial Therapeutics Inc., a clinical-stage biopharmaceutical company dedicated to the development of gut-targeted, small molecule therapeutics for neurological conditions and oncology, today announced that A. Stewart Campbell, Ph.D., chief executive officer, will present an overview of the company and take part in one-on-one meetings with institutional investors at the Jefferies Microbiome-based Therapeutics Summit on April 22, 2021. The summit is a virtual event and the presentation will be accessible to conference registrants for 30 days.

About Axial Therapeutics

Axial Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of gut-targeted, small molecule therapeutics to treat neurological conditions and cancer. The company is leveraging its expertise in the microbiome-gut-brain axis and its unique “omics” approach to discover and advance novel therapies that have the potential to transform paradigms in neurology and oncology. Axial is advancing a pipeline of product candidates with lead clinical programs that address underlying pathology and resulting symptoms in Autism Spectrum Disorder (ASD) and Parkinson’s Disease (PD). For more information, visit https://axialtx.com.

Copyright: 
Copyright Business Wire 2021